David R. Wells's most recent trade in Heart Test Laboratories Inc was a trade of 25,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Heart Test Laboratories Inc | David R. Wells | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Heart Test Laboratories Inc | David R. Wells | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 6,000 | 6,000 | - | - | Employee Stock Option (Right to Buy) | |
| Heart Test Laboratories Inc | David R. Wells | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2023 | 50,000 | 50,000 | - | - | Director Stock Option (Right to Buy) | |
| ENDRA Life Sciences Inc | David R. Wells | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2021 | 25,000 | 25,000 | - | - | Stock Options | |
| ENDRA Life Sciences Inc | David R. Wells | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.90 per share. | 05 Jan 2021 | 34,900 | 80,003 | - | 0.9 | 31,410 | Common Stock |
| ENDRA Life Sciences Inc | David R. Wells | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.90 per share. | 05 Jan 2021 | 100 | 114,903 | - | 0.9 | 90 | Common Stock |